SCHEMBL24744879

SCHEMBL24744879

Cc1nc2c(C(=O)O)ccc(Br)c2n1CC(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CACNA1B Q00975 1/20 0.35
MAPT P10636 2/20 0.33
HTT P42858 2/20 0.33
KMT2A Q03164 1/20 0.33
POLB P06746 1/20 0.33
F2 P00734 1/20 0.33
JAK2 O60674 1/20 0.32
JAK1 P23458 1/20 0.32
JAK3 P52333 1/20 0.32
PLA2G7 Q13093 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
AKR1B10 O60218 2/20 0.31
EPRS1 P07814 1/20 0.31
PTGER4 P35408 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24744892 0.89 KDM4E (0.39) KDM4EALDH1A1CACNA1BKMT2AF2
SCHEMBL31090655 0.88 TLR7 (0.37) KDM4EALDH1A1CACNA1BMAPTHTT
SCHEMBL24742725 0.88 TLR7 (0.37) KDM4EALDH1A1CACNA1BMAPTHTT
SCHEMBL30938924 0.87 KDM4E (0.37) KDM4EALDH1A1CACNA1BKMT2AJAK2
SCHEMBL31090637 0.87 KDM4E (0.37) KDM4EALDH1A1CACNA1BKMT2AJAK2
SCHEMBL24745424 0.87 KDM4E (0.37) KDM4EALDH1A1CACNA1BKMT2AJAK2
SCHEMBL31090615 0.86 JAK2 (0.39) KDM4EALDH1A1CACNA1BMAPTKMT2A
SCHEMBL24744853 0.86 JAK2 (0.39) KDM4EALDH1A1CACNA1BMAPTKMT2A
SCHEMBL24744761 0.80 KDM4E (0.46) KDM4EALDH1A1CACNA1BHTTKMT2A
SCHEMBL30952847 0.80 KDM4E (0.46) KDM4EALDH1A1CACNA1BHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294499-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2024-09-05 US disclosed
CN-117957218-A Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins 凯普托尔治疗学股份有限公司 2024-04-30 CN disclosed
WO-2022253713-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2022-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294499-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN MCL1, MDM2, XIAP KDM4E 1943/4885ALDH1A1 956/4885CACNA1B 4588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.